CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2005-03-11): Bristol-Myers hepatitis drug impressive - US panel


Bristol-Myers hepatitis drug impressive - US panel

Last Updated: 2005-03-11 16:16:01 -0400 (Reuters Health)

GAITHERSBURG, Md. (Reuters) - U.S. health experts on Friday praised the effectiveness of Bristol-Myers Squibb Co.'s experimental hepatitis B drug and recommended the Food and Drug Administration approve it to treat the disease in adults.

The advisory panel voted unanimously to support the drug, entecavir, saying data showed it was superior to other available medicines.

The FDA usually follows the advice of its advisory panels.

"I'm impressed by what I've seen today," said panelist Lynn Paxton of the Centers for Disease Control and Prevention.

Company officials told the panelists that data from clinical trials showed entecavir was more potent than other approved hepatitis drugs, including GlaxoSmithKline Plc's Epivir and Gilead Sciences Inc.'s Hepsera.

It was also stronger than rival hepatitis drug telbivudine, which is being developed by Novartis AG and Idenix Pharmaceuticals Inc., Bristol officials said.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.